This company is no longer active
Magenta Therapeutics Past Earnings Performance
Past criteria checks 0/6
Magenta Therapeutics's earnings have been declining at an average annual rate of -6.3%, while the Biotechs industry saw earnings growing at 22.7% annually.
Key information
-6.3%
Earnings growth rate
41.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -92.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Dec 10
Magenta Therapeutics downgraded to neutral at Goldman Sachs on clarity over candidate
Aug 25Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Jul 13Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Apr 12Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Dec 16Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Aug 26Magenta Therapeutics (MGTA) EHA Investor Presentations - Slideshow
Jun 18We're Not Very Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Rate
May 09Magenta Therapeutics EPS beats by $0.04
May 06What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Mar 17Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Jan 23
Magenta Therapeutics announces expected 2021 highlights milestones
Jan 11What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Dec 01Revenue & Expenses Breakdown
How Magenta Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -69 | 23 | 35 |
| 31 Mar 23 | 0 | -83 | 25 | 47 |
| 31 Dec 22 | 0 | -76 | 26 | 55 |
| 30 Sep 22 | 0 | -76 | 27 | 52 |
| 30 Jun 22 | 0 | -77 | 28 | 52 |
| 31 Mar 22 | 0 | -77 | 28 | 52 |
| 31 Dec 21 | 0 | -71 | 28 | 47 |
| 30 Sep 21 | 0 | -70 | 28 | 46 |
| 30 Jun 21 | 0 | -70 | 27 | 47 |
| 31 Mar 21 | 0 | -72 | 28 | 48 |
| 31 Dec 20 | 0 | -75 | 28 | 51 |
| 30 Sep 20 | 0 | -80 | 27 | 57 |
| 30 Jun 20 | 0 | -83 | 27 | 62 |
| 31 Mar 20 | 0 | -82 | 25 | 63 |
| 31 Dec 19 | 0 | -77 | 24 | 59 |
| 30 Sep 19 | 0 | -70 | 23 | 53 |
| 30 Jun 19 | 0 | -65 | 23 | 48 |
| 31 Mar 19 | 0 | -61 | 21 | 44 |
| 31 Dec 18 | 0 | -58 | 19 | 41 |
| 30 Sep 18 | 0 | -49 | 16 | 35 |
| 30 Jun 18 | 0 | -40 | 12 | 28 |
| 31 Mar 18 | 0 | -42 | 10 | 32 |
| 31 Dec 17 | 0 | -36 | 8 | 28 |
Quality Earnings: MGTA is currently unprofitable.
Growing Profit Margin: MGTA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MGTA is unprofitable, and losses have increased over the past 5 years at a rate of 6.3% per year.
Accelerating Growth: Unable to compare MGTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MGTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-31.3%).
Return on Equity
High ROE: MGTA has a negative Return on Equity (-92.08%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/11 14:03 |
| End of Day Share Price | 2023/09/11 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Magenta Therapeutics, Inc. is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Yun Zhong | BTIG |
| Edward White | H.C. Wainwright & Co. |